Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study

Thomas Pabst, Cristina Papayannidis, Fatih Demırkan, Vadim Doronin, Laura Maria Fogliatto, Christina Guttke, Emmanuel Gyan, Nada Hamad, Pilar Herrera, Anna Hultberg, Julie Jacobs, Amy J. Wagoner Johnson, Angélique Langlois, Xuewen Ma, Giovanni Martinelli, Montserrat Arnán, Rouven Müller, Kerri Nottage, Yishai Ofran, Muhıt Özcan, Olga Samoilova, Jaszianne A Tolbert, Géralyn C. Trudel, Liang Xiu, Norbert Vey, Andrew H. Wei